[1]刘道佳,吴君心,唐明灯,等.18F-FLT PET/CT显像评估复发脑胶质瘤患者预后的价值[J].国际放射医学核医学杂志,2018,(5):403-408.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
　Liu Daojia,Wu Junxin,Tang Mingdeng,et al.Prognostic value of 18F-FLT PET/CT imaging in patients with recurrent gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):403-408.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
点击复制

18F-FLT PET/CT显像评估复发脑胶质瘤患者预后的价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第5期
页码:
403-408
栏目:
临床研究
出版日期:
2018-10-01

文章信息/Info

Title:
Prognostic value of 18F-FLT PET/CT imaging in patients with recurrent gliomas
作者:
刘道佳1;  吴君心2;  唐明灯1;  林端瑜1;  张杰平1;  李生栩1;  蔡志华1;  吕清湖1
1. 350014 福州, 福建省肿瘤医院, 福建医科大学附属肿瘤医院核医学科;
2. 350014 福州, 福建省肿瘤医院, 福建医科大学附属肿瘤医院放疗科
Author(s):
Liu Daojia1;  Wu Junxin2;  Tang Mingdeng1;  Lin Duanyu1;  Zhang Jieping1;  Li Shengxu1;  Cai Zhihua1;  Lyu Qinghu1
1. Department of Nuclear Medicine, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China;
2. Department of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China
关键词:
神经胶质瘤; 肿瘤复发; 局部; 预后; 正电子发射断层显像计算机体层摄影术; 脱氧葡萄糖; 胸苷
Keywords:
Glioma;  Neoplasm recurrence;  local;  Prognosis;  Positron emission tomography computed tomography;  Deoxyglucose;  Thymidine
DOI:
10.3760/cma.j.issn.1673-4114.2018.05.003
摘要:
目的 探讨18F-脱氧胸腺嘧啶核苷（FLT）PET/CT显像中的肿瘤增殖体积（PV）在评估复发脑胶质瘤患者预后中的价值。方法 回顾性分析2012年1月至2016年1月行18F-FLT PET/CT与18F-氟脱氧葡萄糖（FDG）PET/CT检查、经病理结果或临床随访证实为复发的20例脑胶质瘤患者的临床资料。在18F-FLT PET/CT图像上测量复发肿瘤的最大标准化摄取值与正常脑组织的平均标准化摄取值的比值（T/NFLT）、最大直径和PV，在18F-FDG PET/CT图像上测量复发肿瘤的T/NFDG。随访时间截至2016年12月。采用Kaplan-Meier分析法进行生存分析，组间比较采用log-rank检验；采用比例风险回归（Cox）模型对PV、最大直径、T/NFDG、T/NFLT及其他相关临床因素与预后关系进行单因素和多因素分析。结果 20例复发脑胶质瘤患者的中位生存时间为7个月。PV、T/NFLT、最大直径、T/NFDG、年龄预测长生存期的最佳阈值分别为12.565 cm3、7.752、2.800 cm、1.192、52岁，对应的ROC曲线下面积（AUC）分别为0.958、0.865、0.745、0.646、0.667。Kaplan-Meier单因素分析结果显示，复发灶不同PV（<12.565 cm3与≥12.565 cm3）、T/NFLT（<7.752与≥7.752）、肿瘤最大直径（<2.800 cm与≥2.800 cm）、T/NFDG（<1.192与≥1.192）、首次病理结果（Ⅱ级与Ⅲ、Ⅳ级）间的生存曲线差异均有统计学意义（χ2=12.587、12.219、4.285、5.955、6.787，均P<0.05）。Cox模型单因素分析结果显示，20例复发脑胶质瘤患者的预后与PV、T/NFLT、T/NFDG、首次病理结果有关，危险比分别为0.113（95% CI：0.024～0.530）、0.105（95% CI：0.021～0.513）、0.314（95% CI：0.109～0.903）、0.262（95% CI：0.082～0.838），差异均有统计学意义（均P<0.05）。Cox回归模型多因素分析结果显示，肿瘤PV是复发脑胶质瘤患者生存预后的独立影响因素。结论 18F-FLT PET/CT显像中的肿瘤PV可以作为复发脑胶质瘤患者预后的评估指标。
Abstract:
Objectives To evaluate the prognostic value of proliferation volume (PV) measured by pretreating patients with recurrent gliomas with 18F-fluorothymidine (FLT) PET/CT imaging. Methods The clinical data of 20 patients that underwent 18F-FDG PET/CT and 18F-FLT PET/CT examinations from January 2012 to January 2016 showed that recurrent gliomas were retrospectively analyzed. We measured the ratio of the maximum standard uptake value of the tumor to the mean standard uptake value of the normal brain tissue (T/NFLT), PV, and maximum diameter via 18F-FLT PET/CT imaging, T/NFDG was measured by 18F-FDG PET/CT imaging. The follow-up time lasted until December 2016. Result The median survival time of 20 patients with recurrent gliomas was 7 months. The optimal PV, T/NFLT, diameter, T/NFDG, and age cut-off values were 12.565 cm3, 7.752, 2.800 cm, 1.192, and 52 years, with the area under the curve values of 0.958, 0.865, 0.745, 0.646, and 0.667, respectively. Kaplan-Meier single factor analysis revealed that the survival times significantly differed among patients with different PV (<12.565 cm3 vs. ≥ 12.565 cm3), T/NFLT (<7.752 vs. >7.752), maximum diameter (<2.800 cm vs. >2.800 cm), and T/NFDG values (<1.192 vs. >1.192), as well as different pathologies of the first operation (WHO Ⅱ vs. WHO Ⅲ and Ⅲ) (χ2=12.587, 12.219, 4.285, 5.955, 6.787; all P<0.05). Cox single-factor analyses indicated that PV, T/NFLT, T/NFDG, and pathology were the risk factors of survival, with the hazard ratios of 0.113 (95% CI:0.024-0.530), 0.105 (95% CI:0.021-0.513), 0.314 (95% CI:0.109-0.903), and 0.262 (95% CI:0.082-0.838), respectively. Cox multifactor analyses indicated that PV was an independent predictor of survival risk. Conclusion PV is an important factor in the prognosis prediction of patients with recurrent gliomas via 18F-FLT PET/CT imaging.

参考文献/References:

[1] 刘道佳, 唐明灯, 林端瑜, 等. 18F-FDG与18F-FLT PET/CT诊断脑胶质瘤综合治疗后复发的对比研究[J]. 中华核医学与分子影像杂志, 2017, 37 (4):198-201. DOI:10.3760/cma.j.issn.2095-2848. 2017.04.002 Liu DJ, Tang MD, Lin DY, et al. Comparison on the diagnostic values of 18F-FDG and 18F-FLT PET/CT in patients with suspicious recurrence of glioma after multimodal treatment[J]. Chin J Nucl Med Mol Imaging, 2017, 37 (4):198-201.
[2] Kamiya-Matsuoka C, Gilbert MR. Treating recurrent glioblastoma:an update[J]. CNS Oncol, 2015, 4 (2):91-104. DOI:10.2217/cns.14.55.
[3] Santra A, Kumar R, Sharma P, et al. F-18 FDG PET-CT for predicting survival in patients with recurrent glioma:a prospective study[J]. Neuroradiology, 2011, 53 (12):1017-1024. DOI:10.1007/s00234-011-0898-3.
[4] Thiele F, Ehmer J, Piroth MD, et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma[J]. Phys Med Biol, 2009, 54 (18):5525-5539. DOI:10.1088/0031-9155/54/18/012.
[5] Karunanithi S, Sharma P, Kumar A, et al. Can 18F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study[J]. Eur J Radiol, 2014, 83 (1):219-225. DOI:10.1016/j.ejrad.2013.09.004.
[6] Yamamoto Y, Ono Y, Aga F, et al. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas[J]. J Nucl Med, 2012, 53 (12):1911-1915. DOI:10.2967/jnumed.112.104729.
[7] Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3’-deoxy-3’-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab[J]. J Nucl Med, 2012, 53 (1):29-36. DOI:10.2967/jnumed.111. 092387.
[8] Schiepers C, Dahlbom M, Chen W, et al. Kinetics of 3’-deoxy-3’-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma[J]. J Nucl Med, 2010, 51 (5):720-727. DOI:10.2967/jnumed.109068361.
[9] Idema AJ, Hoffmann AL, Boogaarts HD, et al. 3’-Deoxy-3’-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients[J]. J Nucl Med, 2012, 53 (12):1904-1910. DOI:10.2967/jnumed.112.105544.
[10] 董烨, 吴湖炳, 王全师, 等. 18F-FDG PET/CT多次显像在监测和预测非小细胞肺癌术后复发和转移中的价值[J]. 中华核医学与分子影像学杂志, 2014, 34 (2):81-85. DOI:10.3760/cma.j.issn.2095-2848.2014.02.001. Dong Y, Wu HB, Wang QS, et al. Prediction of postoperative recurrence and metastasis with 18F-FDG PET/CT in patients with non-small cell lung cancer[J]. Chin J Nucl Med Mol Imaging, 2014, 34 (2):81-85.
[11] 谢彦婷, 郑容. 18F-FDG PET/CT在食管癌放疗中的应用[J]. 国际放射医学核医学杂志, 2013, 37 (1):42-46. DOI:10.3760/cma.j.issn.1673-4114.2013.01.012. Xie YT, Zheng R. The application of 18F-FDG PET/CT in the radiotherapy of esophageal cancer[J]. Int J Radiat Med Nucl Med, 2013, 37 (1):42-46.
[12] 陈丹丹, 吴湖炳, 王全师, 等. 18F-FDG PET/CT在复发宫颈癌疗效评价及预后预测中的价值[J]. 中华核医学与分子影像学杂志, 2015, 35 (3):168-172. DOI:10.3760/cma.j.issn.2095-2848. 2015. 03.003. Chen DD, Wu HB, Wang QS, et al. Value of 18F-FDG PET/CT in the evaluation of treatment response and prognosis for patients with recurrent uterine cervical cancer[J]. Chin J Nucl Med Mol Imaging, 2015, 35 (3):168-172.
[13] 戴云秀, 杨光杰, 王振光, 等. 18F-FDG PET/CT基线SUVmax在滤泡性淋巴瘤侵袭性、分期评价中的价值及其与中期疗效的相关性研究[J]. 国际放射医学核医学杂志, 2018, 42 (2):104-110. DOI:10.3760/cma.j.issn.1673-4114.2018.02.002. Dai YX, Yang GJ, Wang ZG, et al. Evaluation of invasiveness, staging, and correlation with interim therapeutic response based on baseline 18F-FDG PET/CT SUVmax in patients with follicular lymphoma[J]. Int J Radiat Med Nucl Med, 2018, 42 (2):104-110.
[14] Colavolpe C, Chinot O, Metellus P, et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan[J]. Neuro Oncol, 2012, 14 (5):649-657. DOI:10.1093/neuonc/nos012.

相似文献/References:

[1]程勇军,赵晋华.东亚钳蝎氯毒素在胶质瘤靶向显像与治疗中的研究进展[J].国际放射医学核医学杂志,2015,39(1):32.[doi:10.3760/cma.j.issn.1673-4114.2015.01.008]
　Cheng Yongjun,Zhao Jinhua.Development of research in targeting image and therapy of gliomas using Buthus martensii Karsch chlorotoxin[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):32.[doi:10.3760/cma.j.issn.1673-4114.2015.01.008]
[2]高艳,赵晋华.PET/MRI融合显像在脑胶质瘤诊断和治疗中的研究进展[J].国际放射医学核医学杂志,2015,39(1):71.[doi:10.3760/cma.j.issn.1673-4114.2015.01.015]
　Gao Yan,Zhao Jinhua.The advancement of PET/MRI on the diagnosis and treatment of brain gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):71.[doi:10.3760/cma.j.issn.1673-4114.2015.01.015]
[3]周惠君,董萍,沈国华,等.11C-蛋氨酸PET/CT显像在脑胶质瘤中的应用价值[J].国际放射医学核医学杂志,2015,39(2):161.[doi:10.3760/cma.j.issn.1673-4114.2015.02.013]
　Zhou Huijun,Dong Ping,Shen Guohua,et al.Value of 11C-methionine PET/CT imaging indiagnosing cerebral glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):161.[doi:10.3760/cma.j.issn.1673-4114.2015.02.013]
[4]周新韩,高明勇,张仙海,等.磁敏感加权成像显示肿瘤内静脉评价胶质瘤分级[J].国际放射医学核医学杂志,2014,38(6):373.[doi:10.3760/cma.j.issn.1673-4114.2014.06.006]
　Zhou Xin-han,Gao Ming-yong,Zhang Xian-hai,et al.Values of tumor vein detected by susceptibility weighted imaging in evaluation of gliomas grade[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):373.[doi:10.3760/cma.j.issn.1673-4114.2014.06.006]
[5]李平,宗天舟,季晓芹,等.CD133+U87人脑胶质瘤干细胞放射敏感性和DNA双链断裂损伤修复的实验研究[J].国际放射医学核医学杂志,2013,37(3):153.[doi:10.3760/cma.j.issn.1673-4114.2013.03.007]
　LI Ping,ZONG Tian-zhou,JI Xiao-qin,et al.CD133 positive U87 glioma stem cell radiosensitivity and DNA double-strand break repair[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):153.[doi:10.3760/cma.j.issn.1673-4114.2013.03.007]
[6]展凤麟,汪世存,潘博,等.11C-胆碱和18F-FDG PET/CT显像在脑胶质瘤诊断中的应用[J].国际放射医学核医学杂志,2013,37(4):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
　ZHAN Feng-lin,WANG Shi-cun,PAN Bo,et al.Application of 11C-choline and 18F-FDG PET/CT in diagnosing brain glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):193.[doi:10.3760/cma.j.issn.1673-4114.2013.04.001]
[7]李立芳,韩宝林.早期乳腺癌根治术后辅助放疗指征探讨[J].国际放射医学核医学杂志,2013,37(5):287.[doi:10.3760/cma.j.issn.1673-4114.2013.05.009]
　LI Li-fang,HAN Bao-lin.Indications for postmastectomy radiotherapy in early breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):287.[doi:10.3760/cma.j.issn.1673-4114.2013.05.009]
[8]王志军,许祖闪,丛英珍,等.高场强MRI与X线钡餐造影、胃镜诊断胃癌术后复发的对比分析[J].国际放射医学核医学杂志,2012,36(1):46.[doi:10.3760/cma.j.issn.1673-4114.2012.01.012]
　WANG Zhi-jun,XU Zu-shan,CONG Ying-zhen,et al.The diagnosis of recurrent gastric carcinoma: high-field-strength MRI compared with barium meal of alimentary canal and gastroscope[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):46.[doi:10.3760/cma.j.issn.1673-4114.2012.01.012]
[9]李鹏,赵卫威,杨建伟.18F-FDG PET-CT在探测卵巢癌术后复发与转移中的应用价值[J].国际放射医学核医学杂志,2012,36(6):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
　LI Peng,ZHAO Wei-wei,YANG Jian-wei.18F-FDG PET-CT imaging in the detection of recurrent and metastasis ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):348.[doi:10.3760/cma.j.issn.1673-4114.2012.06.007]
[10]杨辉,张富强,李文亮,等.术中125Ⅰ粒子植入治疗复发性脑胶质瘤的临床研究[J].国际放射医学核医学杂志,2013,37(6):345.[doi:10.3760/cma.j.issn.1673-4114.2013.06.005]
　YANG Hui,ZHANG Fu-qiang,LI Wen-liang,et al.Clinical study of operation combined with 125Ⅰ seeds implantation in the treatment of recurrent cerebral glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):345.[doi:10.3760/cma.j.issn.1673-4114.2013.06.005]

备注/Memo

备注/Memo:
收稿日期:2018-04-19。
基金项目:国家临床重点专科建设项目（（2013）544）；福建省卫生与计划生育委员会青年科研课题（2015-2-5）
通讯作者:唐明灯,Email:tmd0603@126.com
更新日期/Last Update: 2018-10-01